| Dr Barbara E Swartz, MD, PHD | |
|
2122 Health Dr Sw Ste 160, Wyoming, MI 49519-9402 | |
| (616) 252-5790 | |
| Not Available |
| Full Name | Dr Barbara E Swartz |
|---|---|
| Gender | Female |
| Speciality | Neurology |
| Experience | 45 Years |
| Location | 2122 Health Dr Sw Ste 160, Wyoming, Michigan |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811082324 | NPI | - | NPPES |
| 1811082324 | Medicaid | NV | |
| 10974294 | Other | CAQH |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Arrowhead Neurosurgical Medical Group Inc | 7315900644 | 15 |
| Osf Multi-specialty Group | 3678889789 | 1543 |
News Archive
Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.
"Bake sales saved the nonprofit Athol Memorial Hospital the first time around, Steve Penka says with a smile. Eleven years later, it took a big Tennessee-based, for-profit hospital chain to keep it in business," the (Worcester, Mass.) Telegram & Gazette reports. In light of a recent report by Massachusetts Attorney General Martha Coakley's office, many are surprised Athol is around at all.
Sydney University medical researchers have secured more than $19.4 million for their work on cardiovascular and liver diseases and HIV/AIDS in the latest round of National Health and Medical Research Council program grants.
A large study of Swedish men found that those who were even mildly overweight around age 18 were more likely develop cardiomyopathy in adulthood - an uncommon heart muscle condition that can cause heart failure, according to new research in the American Heart Association's journal Circulation.
Gentel Biosciences, a leader in proteomics discovery tools, today launched the Gentel Proteomics Multi-System™ providing "scan-to-analysis" functionality for multiplex immunoassays, lysate and antigen arrays as well as Western Blot, ELISA and tissue imaging, delivering multi-application value to researchers worldwide.
› Verified 3 days ago
| Entity Name | County Of Santa Clara |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659450955 PECOS PAC ID: 1254244973 Enrollment ID: O20040113000757 |
News Archive
Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.
"Bake sales saved the nonprofit Athol Memorial Hospital the first time around, Steve Penka says with a smile. Eleven years later, it took a big Tennessee-based, for-profit hospital chain to keep it in business," the (Worcester, Mass.) Telegram & Gazette reports. In light of a recent report by Massachusetts Attorney General Martha Coakley's office, many are surprised Athol is around at all.
Sydney University medical researchers have secured more than $19.4 million for their work on cardiovascular and liver diseases and HIV/AIDS in the latest round of National Health and Medical Research Council program grants.
A large study of Swedish men found that those who were even mildly overweight around age 18 were more likely develop cardiomyopathy in adulthood - an uncommon heart muscle condition that can cause heart failure, according to new research in the American Heart Association's journal Circulation.
Gentel Biosciences, a leader in proteomics discovery tools, today launched the Gentel Proteomics Multi-System™ providing "scan-to-analysis" functionality for multiplex immunoassays, lysate and antigen arrays as well as Western Blot, ELISA and tissue imaging, delivering multi-application value to researchers worldwide.
› Verified 3 days ago
| Entity Name | County Of Santa Clara |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699885079 PECOS PAC ID: 1254244973 Enrollment ID: O20040113000784 |
News Archive
Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.
"Bake sales saved the nonprofit Athol Memorial Hospital the first time around, Steve Penka says with a smile. Eleven years later, it took a big Tennessee-based, for-profit hospital chain to keep it in business," the (Worcester, Mass.) Telegram & Gazette reports. In light of a recent report by Massachusetts Attorney General Martha Coakley's office, many are surprised Athol is around at all.
Sydney University medical researchers have secured more than $19.4 million for their work on cardiovascular and liver diseases and HIV/AIDS in the latest round of National Health and Medical Research Council program grants.
A large study of Swedish men found that those who were even mildly overweight around age 18 were more likely develop cardiomyopathy in adulthood - an uncommon heart muscle condition that can cause heart failure, according to new research in the American Heart Association's journal Circulation.
Gentel Biosciences, a leader in proteomics discovery tools, today launched the Gentel Proteomics Multi-System™ providing "scan-to-analysis" functionality for multiplex immunoassays, lysate and antigen arrays as well as Western Blot, ELISA and tissue imaging, delivering multi-application value to researchers worldwide.
› Verified 3 days ago
| Entity Name | Arrowhead Neurosurgical Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639255854 PECOS PAC ID: 7315900644 Enrollment ID: O20041108001131 |
News Archive
Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.
"Bake sales saved the nonprofit Athol Memorial Hospital the first time around, Steve Penka says with a smile. Eleven years later, it took a big Tennessee-based, for-profit hospital chain to keep it in business," the (Worcester, Mass.) Telegram & Gazette reports. In light of a recent report by Massachusetts Attorney General Martha Coakley's office, many are surprised Athol is around at all.
Sydney University medical researchers have secured more than $19.4 million for their work on cardiovascular and liver diseases and HIV/AIDS in the latest round of National Health and Medical Research Council program grants.
A large study of Swedish men found that those who were even mildly overweight around age 18 were more likely develop cardiomyopathy in adulthood - an uncommon heart muscle condition that can cause heart failure, according to new research in the American Heart Association's journal Circulation.
Gentel Biosciences, a leader in proteomics discovery tools, today launched the Gentel Proteomics Multi-System™ providing "scan-to-analysis" functionality for multiplex immunoassays, lysate and antigen arrays as well as Western Blot, ELISA and tissue imaging, delivering multi-application value to researchers worldwide.
› Verified 3 days ago
| Entity Name | Emergency Associates Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003866120 PECOS PAC ID: 8022196518 Enrollment ID: O20080424000144 |
News Archive
Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.
"Bake sales saved the nonprofit Athol Memorial Hospital the first time around, Steve Penka says with a smile. Eleven years later, it took a big Tennessee-based, for-profit hospital chain to keep it in business," the (Worcester, Mass.) Telegram & Gazette reports. In light of a recent report by Massachusetts Attorney General Martha Coakley's office, many are surprised Athol is around at all.
Sydney University medical researchers have secured more than $19.4 million for their work on cardiovascular and liver diseases and HIV/AIDS in the latest round of National Health and Medical Research Council program grants.
A large study of Swedish men found that those who were even mildly overweight around age 18 were more likely develop cardiomyopathy in adulthood - an uncommon heart muscle condition that can cause heart failure, according to new research in the American Heart Association's journal Circulation.
Gentel Biosciences, a leader in proteomics discovery tools, today launched the Gentel Proteomics Multi-System™ providing "scan-to-analysis" functionality for multiplex immunoassays, lysate and antigen arrays as well as Western Blot, ELISA and tissue imaging, delivering multi-application value to researchers worldwide.
› Verified 3 days ago
| Entity Name | County Of Santa Clara |
|---|---|
| Entity Type | Part B Supplier - Other Medical Care Group |
| Entity Identifiers | NPI Number: 1629301346 PECOS PAC ID: 1254244973 Enrollment ID: O20110318000170 |
News Archive
Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.
"Bake sales saved the nonprofit Athol Memorial Hospital the first time around, Steve Penka says with a smile. Eleven years later, it took a big Tennessee-based, for-profit hospital chain to keep it in business," the (Worcester, Mass.) Telegram & Gazette reports. In light of a recent report by Massachusetts Attorney General Martha Coakley's office, many are surprised Athol is around at all.
Sydney University medical researchers have secured more than $19.4 million for their work on cardiovascular and liver diseases and HIV/AIDS in the latest round of National Health and Medical Research Council program grants.
A large study of Swedish men found that those who were even mildly overweight around age 18 were more likely develop cardiomyopathy in adulthood - an uncommon heart muscle condition that can cause heart failure, according to new research in the American Heart Association's journal Circulation.
Gentel Biosciences, a leader in proteomics discovery tools, today launched the Gentel Proteomics Multi-System™ providing "scan-to-analysis" functionality for multiplex immunoassays, lysate and antigen arrays as well as Western Blot, ELISA and tissue imaging, delivering multi-application value to researchers worldwide.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Barbara E Swartz, MD, PHD 2122 Health Dr Sw Ste 160, Wyoming, MI 49519-9402 Ph: (616) 252-5790 | Dr Barbara E Swartz, MD, PHD 2122 Health Dr Sw Ste 160, Wyoming, MI 49519-9402 Ph: (616) 252-5790 |
News Archive
Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.
"Bake sales saved the nonprofit Athol Memorial Hospital the first time around, Steve Penka says with a smile. Eleven years later, it took a big Tennessee-based, for-profit hospital chain to keep it in business," the (Worcester, Mass.) Telegram & Gazette reports. In light of a recent report by Massachusetts Attorney General Martha Coakley's office, many are surprised Athol is around at all.
Sydney University medical researchers have secured more than $19.4 million for their work on cardiovascular and liver diseases and HIV/AIDS in the latest round of National Health and Medical Research Council program grants.
A large study of Swedish men found that those who were even mildly overweight around age 18 were more likely develop cardiomyopathy in adulthood - an uncommon heart muscle condition that can cause heart failure, according to new research in the American Heart Association's journal Circulation.
Gentel Biosciences, a leader in proteomics discovery tools, today launched the Gentel Proteomics Multi-System™ providing "scan-to-analysis" functionality for multiplex immunoassays, lysate and antigen arrays as well as Western Blot, ELISA and tissue imaging, delivering multi-application value to researchers worldwide.
› Verified 3 days ago
Rudolph Obo Addy, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2093 Health Dr Sw, Wyoming, MI 49519 Phone: 616-252-5760 | |
Dr. Fazeel Mukhtar Siddiqui, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 5900 Byron Center Ave Sw, Wyoming, MI 49519 Phone: 616-252-7200 | |
Paul G Wasielewski, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2122 Health Drive Sw, Wyoming, MI 49519 Phone: 616-252-5790 Fax: 616-252-5793 | |
Christine Elizabeth Larkin, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2215 44th St Sw, Wyoming, MI 49519 Phone: 616-252-4560 | |
Jordan Taylor, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2122 Health Dr Sw, Wyoming, MI 49519 Phone: 616-252-5790 Fax: 616-252-5793 | |
Aubrey Marie Kuehnel, DO Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2093 Health Dr Sw Ste 302, Wyoming, MI 49519 Phone: 616-252-7264 | |
Jack Neerken Carr, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 3353 Lousma Drive Se, Wyoming, MI 49548 Phone: 616-454-7077 |